Early Pipeline and Value Assessment

In oncology, where innovation moves fast and stakes are high, early-stage teams needed clarity on the real-world, clinical, economic, and system value of next-generation therapies. The opportunity lay in going beyond scientific promise to anticipate, quantify and demonstrate payer priorities, health system constraints, and HTA expectations.

A modular early assessment framework and tools integrated unmet need, value drivers, and HTA-aligned evidence priorities. This enabled smarter decisions on investment, evidence generation, and positioning – reducing risk, increasing confidence and accelerating readiness for go/no-go milestones, optimising integrated access and commercial planning.